CY2200004T2 - Σκευασματα δαπτομυκινης και χρησεις αυτων - Google Patents

Σκευασματα δαπτομυκινης και χρησεις αυτων

Info

Publication number
CY2200004T2
CY2200004T2 CY20152200004T CY152200004T CY2200004T2 CY 2200004 T2 CY2200004 T2 CY 2200004T2 CY 20152200004 T CY20152200004 T CY 20152200004T CY 152200004 T CY152200004 T CY 152200004T CY 2200004 T2 CY2200004 T2 CY 2200004T2
Authority
CY
Cyprus
Prior art keywords
daptomycin preparation
daptomycin
preparation
Prior art date
Application number
CY20152200004T
Other languages
English (en)
Original Assignee
Hospira Australia Pty Ltd
Au/Au]
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50277707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2200004(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hospira Australia Pty Ltd, Au/Au] filed Critical Hospira Australia Pty Ltd
Publication of CY2200004T2 publication Critical patent/CY2200004T2/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
CY20152200004T 2012-09-11 2015-11-20 Σκευασματα δαπτομυκινης και χρησεις αυτων CY2200004T2 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261699570P 2012-09-11 2012-09-11
US201361839699P 2013-06-26 2013-06-26
PCT/IB2013/002191 WO2014041425A1 (en) 2012-09-11 2013-09-11 Daptomycin formulations and uses thereof

Publications (1)

Publication Number Publication Date
CY2200004T2 true CY2200004T2 (el) 2016-02-10

Family

ID=50277707

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20152200004T CY2200004T2 (el) 2012-09-11 2015-11-20 Σκευασματα δαπτομυκινης και χρησεις αυτων

Country Status (20)

Country Link
US (4) US9655946B2 (el)
EP (2) EP2895187A4 (el)
AU (2) AU2013316779A1 (el)
BR (1) BR112015005400B1 (el)
CA (1) CA2884484C (el)
CL (1) CL2015000608A1 (el)
CY (1) CY2200004T2 (el)
DE (1) DE13837694T1 (el)
DK (1) DK2895187T1 (el)
ES (1) ES2552754T1 (el)
HK (1) HK1207006A1 (el)
HU (1) HUE13837694T1 (el)
IL (1) IL237652B (el)
MX (1) MX366122B (el)
NZ (3) NZ742241A (el)
SA (1) SA515360129B1 (el)
SG (1) SG11201506113WA (el)
TN (1) TN2015000090A1 (el)
WO (1) WO2014041425A1 (el)
ZA (1) ZA201502310B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
US9655946B2 (en) * 2012-09-11 2017-05-23 Hospira Australia Pty Ltd. Daptomycin formulations and uses thereof
EP3528786B1 (en) 2016-10-21 2023-04-05 Xellia Pharmaceuticals ApS Liquid formulations of daptomycin
CN111093625A (zh) 2017-08-31 2020-05-01 埃克斯利亚制药有限公司 达托霉素制剂
CN110339342A (zh) * 2018-04-03 2019-10-18 江苏恒瑞医药股份有限公司 一种达托霉素的盐或含盐的组合物及其制备方法
US11058745B1 (en) 2018-10-04 2021-07-13 Good Health, Llc Stable liquid pharmaceutical compositions of daptomycin
US11173189B2 (en) 2020-03-12 2021-11-16 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
US11857512B2 (en) 2020-07-24 2024-01-02 Genzyme Corporation Pharmaceutical compositions comprising venglustat
CN115590825B (zh) * 2022-10-20 2024-02-02 安士制药(中山)有限公司 一种注射用达托霉素及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5560906A (en) * 1995-03-27 1996-10-01 Oral Technology Laboratories, Inc. Non-alcoholic antimicrobial mouthwash for removal of dental plaque
PL206091B1 (pl) * 1998-09-25 2010-06-30 Cubist Pharmaceuticals Zastosowania daptomycyny
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
WO2002059145A1 (en) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
CN1616083A (zh) * 2004-09-01 2005-05-18 魏雪纹 注射用达托霉素冻干制剂及制备方法
JP2008546429A (ja) * 2005-05-31 2008-12-25 キュービスト ファーマシューティカルズ, インコーポレイテッド バイオフィルム処理およびカテーテル救出のためのダプトマイシン
US20110124551A1 (en) * 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
SG10201407724YA (en) 2009-11-23 2014-12-30 Cubist Pharm Inc Daptomycin compositions and related methods
EP3287138A1 (en) * 2012-08-23 2018-02-28 Agila Specialties Private Limited Improved daptomycin injectable formulation
US9655946B2 (en) * 2012-09-11 2017-05-23 Hospira Australia Pty Ltd. Daptomycin formulations and uses thereof

Also Published As

Publication number Publication date
BR112015005400A2 (pt) 2017-07-04
HK1207006A1 (en) 2016-01-22
SA515360129B1 (ar) 2016-08-15
MX366122B (es) 2019-06-27
EP4066849A1 (en) 2022-10-05
DK2895187T1 (da) 2015-11-16
ZA201502310B (en) 2019-09-25
CA2884484C (en) 2021-01-19
DE13837694T1 (de) 2015-12-31
CA2884484A1 (en) 2014-03-20
US20180177843A1 (en) 2018-06-28
TN2015000090A1 (en) 2016-06-29
AU2018217322A1 (en) 2018-09-06
IL237652B (en) 2020-06-30
ES2552754T1 (es) 2015-12-02
NZ741342A (en) 2019-10-25
US10357535B2 (en) 2019-07-23
NZ742241A (en) 2019-08-30
BR112015005400B1 (pt) 2022-03-08
MX2015003164A (es) 2015-12-16
CL2015000608A1 (es) 2015-11-06
NZ706286A (en) 2018-05-25
IL237652A0 (en) 2015-04-30
US20170216396A1 (en) 2017-08-03
EP2895187A4 (en) 2015-12-02
US20150313958A1 (en) 2015-11-05
US9655946B2 (en) 2017-05-23
AU2013316779A1 (en) 2015-04-02
AU2018217322B2 (en) 2020-08-27
SG11201506113WA (en) 2015-09-29
EP2895187A1 (en) 2015-07-22
WO2014041425A1 (en) 2014-03-20
US20200237858A1 (en) 2020-07-30
HUE13837694T1 (hu) 2016-04-28

Similar Documents

Publication Publication Date Title
LTC2822954I2 (lt) Policikliniai karbamoilpiridino junginiai ir jų farmacinis panaudojimas
CL2014002899A1 (es) Composiciones pesticidas y procesos relacionados con ellas
BR112015003227A2 (pt) processos de clicoconjugação e composições
BR112015003354A8 (pt) métodos e composições de microcápsula
CL2015000027A1 (es) Anticuerpos e inmunoconjugados anti-cd22
DK2858671T3 (da) Antistofformulering
DK3363902T3 (da) Crispr-baseret genommodifikation og -regulering
DK2890397T3 (da) Antiprolactinreceptor-antistofformulering
CO6801776A2 (es) Cosmético
BR112014031820A2 (pt) aduto de politioéter e composição
DK2903600T3 (da) Virusholdig formulering og anvendelse deraf
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
DK2920197T3 (da) Prolinlåste sammenhæftede peptider og anvendelser deraf
DK2864426T3 (da) Justerbare materialer
DK3117837T3 (da) Antistofformuleringer
DK3293183T3 (da) Hæmmerforbindelser
HK1210714A1 (en) Antibody formulations and uses thereof
CY2200004T2 (el) Σκευασματα δαπτομυκινης και χρησεις αυτων
BR112014032798A2 (pt) composição
BR112015009718A2 (pt) composição de matéria e artigo.
BR112013014644A2 (pt) composição farmacêutica e complexo
DK3453723T3 (da) Anti-ASIC1-antistoffer og anvendelser deraf
DK2897594T3 (da) Farmaceutisk sammensætning
DK2868318T3 (da) Injicerbar formulering
NL301064I2 (nl) toltrazuril en gleptoferron